Transcept Pharmaceuticals to Report Second Quarter 20...( RICHMOND Calif. A...),Health
Navigation Links
Transcept Pharmaceuticals to Report Second Quarter 2009 Results
Date:8/6/2009
RICHMOND, Calif., Aug. 6 /PRNewswire-FirstCall/ -- Transcept Pharmaceuticals, Inc. (Nasdaq: TSPT), a specialty pharmaceutical company focused on the development and commercialization of proprietary products that address important therapeutic needs in the field of neuroscience, today announced it will report results for its quarter ended June 30, 2009 on Friday, August 14, 2009, prior to the opening of the market.
A conference call to review the results will begin at 8:30 a.m. ET (5:30 a.m. PT) on August 14, 2009 and will be hosted by Glenn A. Oclassen, President & Chief Executive Officer, and Thomas P. Soloway, Senior Vice President & Chief Financial Officer.
To participate in the conference call, please dial 877-397-0284 (USA) or 719-325-4890 (International). In addition, a dial-up replay of the conference call will be available from August 14, 2009 through August 26, 2009. The replay telephone number is 888-203-1112 (USA) or 719-457-0820 (International), Replay Passcode: 2582954.
A live webcast of the call will also be available from the Investors section on the corporate web site at www.transcept.com. A webcast replay can be accessed on the corporate web site beginning August 14, 2009 at the same time as the conference call and will remain on the site through August 28, 2009.
About Intermezzo(R)
Intermezzo(R) (zolpidem tartrate sublingual tablet), the lead product candidate at Transcept, has the potential to be the first prescription sleep aid specifically approved for use in the middle of the night at the time a patient awakens and has difficulty returning to sleep. Intermezzo(R) is a sublingual low dose formulation of zolpidem, the active agent most commonly prescribed in the Un
'/>"/>
| SOURCE Transcept Pharmaceuticals, Inc. Copyright©2009 PR Newswire. All rights reserved |
Related medicine news :
1. Transcept Pharmaceuticals to Hold Conference Call on Agreement with Purdue Pharmaceutical Products L.P. to Commercialize Intermezzo(R) in the United States
2. Transcept Pharmaceuticals to Present at BMO Capital Markets Healthcare Conference on August 5, 2009
3. Transcept Pharmaceuticals Announces Expected FDA Extension of Regulatory Review Period for Intermezzo(R)
4. Transcept Pharmaceuticals to Present at Needham Life Sciences Conference on June 10, 2009
5. Transcept Pharmaceuticals Presents Data from Studies of Two Product Candidates at Annual Meeting of the American Psychiatric Association
6. Transcept Pharmaceuticals Reports First Quarter 2009 Financial Results
7. Transcept Pharmaceuticals Appoints Joseph T. Kennedy as General Counsel
8. Transcept Pharmaceuticals Reports Fourth Quarter and Year End 2008 Financial Results
9. Transcept Pharmaceuticals to Report Fourth Quarter 2008 Results
10. Transcept Pharmaceuticals to Present at Two Upcoming Conferences
11. Transcept Pharmaceuticals, Inc. Completes Merger with Novacea, Inc.
Post Your Comments:
(Date:11/22/2009)... ,, RSVfoundtocausefarmoreemergencydepartm..., BOSTON,Nov.23/PRNewswire-USNewswire/--Influenza,...tionofpublichealthofficials,themediaandthepublic.H...donpatientsseeninitsemergencydepartment(ED)durings...ratorysyncytialvirus(RSV)-takesasubstantiallygreat...
(Date:11/22/2009)... , A protein known to stimulate blood vessel grow...ll overgrowth in the development of polyps that ch...is, a study by Johns Hopkins researchers suggests....eloping novel therapies to treat this form of the ...ments. , Chronic sinusitis, a constant irritatio...
(Date:11/22/2009)... , In a new study, the amount of television viewe...ubles the previous estimates of early childhood sc...ing significantly more on average than those in ce...xamine screen time in child care settings in more ... in 168 child care programs in four states, and wa...
(Date:11/22/2009)... , , DALLAS Nov. 23, 2009 UT Southwestern Medic... National Institutes of Health to share $56 millio... Consortium (ICAC). , The ICAC, which receives ...lergy and Infectious Diseases, investigates novel ... , Dr. Rebecca Gruchalla, chief of allergy and im...
(Date:11/22/2009)... , The Onder Law Firm&rsq...iew to those or families of those who may have exp...lth problems after taking XOLAIR. , ... -- The Onder Law Firm are among attorneys offeri...blems such as heart attack and stroke. The attorn...
Breaking Medicine News(10 mins):Health News:Amid the Flu Epidemic, Don't Forget RSV in Young Children 2Health News:Amid the Flu Epidemic, Don't Forget RSV in Young Children 3Health News:Johns Hopkins researchers track down protein responsible for chronic rhinosinusitis with polyps 2Health News:Johns Hopkins researchers track down protein responsible for chronic rhinosinusitis with polyps 3Health News:Daycare may double TV time for young children, study finds 2Health News:Daycare may double TV time for young children, study finds 3Health News:Daycare may double TV time for young children, study finds 4Health News:UT Southwestern receives continued NIH funding for Inner City Asthma Consortium 2Health News:The Attorneys of The Onder Law Firm Offers Free XOLAIR Case Review 2[0] Amid the Flu Epidemic, Don't Forget RSV in Young Children[0] Johns Hopkins researchers track down protein responsible for chronic rhinosinusitis with polyps[0] Daycare may double TV time for young children, study finds[0] UT Southwestern receives continued NIH funding for Inner City Asthma Consortium[0] The Attorneys of The Onder Law Firm Offers Free XOLAIR Case Review
...Preventive Services Task Force (USPSTF), updating ...ostate cancer screening for men over the age of 75...r 75 could benefit from screening. , Previously,...ly detection improves health outcomes. The updated...
... A recent study published in American Journal of ...lating agents (ESAs), a widely used drug to treat ... of myeloma patients. In the study, 323 multiple m...ociation between ESA exposure and a reduction in p...
...task force reports , , MONDAY, Aug. 4 (Hea... a dim view of prostate cancer screenings at any a...men over 75. , The over-75 rule "is much more expl...S. Preventive Services Task Force that is updating...
...to $16.9 Million Gross Profit Margin at ...es Lower End of 2008 Revenue Guidance, MINNEAPOLI...ufacturer and marketer of state-of-the-art cardiac..., up 36.1% from $12.4 million reported in the seco...
...eutics, Inc.,a clinical stage biopharmaceutical co...iabetes, metabolism and obesity today announced it...re financing for $18.25,million. The financing was...vestors Sofinnova Ventures and OrbiMed Advisors,al...
....,Agency for International Development,s deputy mi...ctor. The promotion took place this morning after,...e oath of office during a,brief ceremony., "Susan...he key to reaching our ultimate goal of successful...
Other Medicine News:Health News:Treatment with anti-anemia drugs may not be safe for multiple myeloma patients 2Health News:New Guidelines Rule Out Prostate Screening for Men Over 75 2Health News:New Guidelines Rule Out Prostate Screening for Men Over 75 3Health News:New Guidelines Rule Out Prostate Screening for Men Over 75 4Health News:ATS Medical Announces Second Quarter Results 2Health News:ATS Medical Announces Second Quarter Results 3Health News:ATS Medical Announces Second Quarter Results 4Health News:ATS Medical Announces Second Quarter Results 5Health News:ATS Medical Announces Second Quarter Results 6Health News:ATS Medical Announces Second Quarter Results 7Health News:ATS Medical Announces Second Quarter Results 8Health News:ATS Medical Announces Second Quarter Results 9Health News:ATS Medical Announces Second Quarter Results 10Health News:InteKrin Therapeutics Announces $20 Million Series C Financing 2US Preventive Services Task Force updates prostate cancer screening recommendationsTreatment with anti-anemia drugs may not be safe for multiple myeloma patientsNew Guidelines Rule Out Prostate Screening for Men Over 75ATS Medical Announces Second Quarter ResultsInteKrin Therapeutics Announces $20 Million Series C FinancingUSAID Announces New Mission Director to Colombia
(Date:11/21/2009)..., WASHINGTON, Nov. 21 An urgent ne... diseases in the developing world has prompted a g...earchers, non-profit product development partnersh...ompanies. As noted today in a symposium at the 58t...al Medicine and Hygiene (ASTMH), these collaborati...
(Date:11/20/2009)..., WAYNE, Pa., Nov. 20 E...ed the results for its fiscal first quarter ended ...of fiscal 2010, product revenue decreased approxim...three-month period ended September 30, 2009 as com...mpany reported the decreased net revenue of $8,434...
(Date:11/20/2009)... , BOSTON, Nov. 20 The United S...ld an earlier District Court ruling yesterday, app...olesale Price (AWP) pharmaceutical litigation agai...o: http://www.newscom.com/cgi-bin/prnh/20080317/A...that awarded consumers who purchased the pharmaceu...
Breaking Medicine Technology:ASTMH Symposium Showcases Efforts To Meet the Need for New Medicines to Treat Infectious Diseases in Developing Countries 2ASTMH Symposium Showcases Efforts To Meet the Need for New Medicines to Treat Infectious Diseases in Developing Countries 3Escalon(R) Reports First Quarter Fiscal 2010 Results 2Escalon(R) Reports First Quarter Fiscal 2010 Results 3Escalon(R) Reports First Quarter Fiscal 2010 Results 4Escalon(R) Reports First Quarter Fiscal 2010 Results 5Escalon(R) Reports First Quarter Fiscal 2010 Results 6Escalon(R) Reports First Quarter Fiscal 2010 Results 7U.S. Court of Appeals Upholds AstraZeneca AWP Settlement 2U.S. Court of Appeals Upholds AstraZeneca AWP Settlement 3U M Doctor Working to Get Neurologists in the Game When it Comes to Sports Injuries 59318 1U M Doctor Working to Get Neurologists in the Game When it Comes to Sports Injuries 59318 2U M Doctor Working to Get Neurologists in the Game When it Comes to Sports Injuries 59318 3Regence Video Asks What if Everything Worked Like Health Care 3F 59316 1Regence Video Asks What if Everything Worked Like Health Care 3F 59316 2Regence Video Asks What if Everything Worked Like Health Care 3F 59316 3Clinical Remissions in Three Otherwise Intractable Cancers Signal the Progress of Targeted Genetic Medicine 14438 1Clinical Remissions in Three Otherwise Intractable Cancers Signal the Progress of Targeted Genetic Medicine 14438 2Clinical Remissions in Three Otherwise Intractable Cancers Signal the Progress of Targeted Genetic Medicine 14438 3...s Enrolled and Being Treated, BETHESDA, Md., Dec.... Board: NWBO) (AIM: NWBT; NWBS) ("NWBT"),today ann...t 30 patients,using DCVax(R)-L for recurrent ovari...ania Center for Research on Early Detection and Cu...r. The first patients have been,enrolled and have ...
...Minn., Dec. 21 William Fals-Stewart,Ph.D., profes...Rochester in,Rochester, New York, has earned the 2... documents the benefits of partner involvement in ...he Butler Center for Research,at Hazelden, the awa...er,who has advanced the scientific knowledge of ad...
Other Medicine Technology:Northwest Biotherapeutics Conducting Ovarian Cancer Clinical Trial With DCVax(R)-L at University of Pennsylvania 2Northwest Biotherapeutics Conducting Ovarian Cancer Clinical Trial With DCVax(R)-L at University of Pennsylvania 3Northwest Biotherapeutics Conducting Ovarian Cancer Clinical Trial With DCVax(R)-L at University of Pennsylvania 4Northwest Biotherapeutics Conducting Ovarian Cancer Clinical Trial With DCVax(R)-L at University of Pennsylvania 5Northwest Biotherapeutics Conducting Ovarian Cancer Clinical Trial With DCVax(R)-L at University of Pennsylvania 6Fals-Stewart Earns Hazelden's 2007 Dan Anderson Research Award 2Fals-Stewart Earns Hazelden's 2007 Dan Anderson Research Award 3Fals-Stewart Earns Hazelden's 2007 Dan Anderson Research Award 4| Copyright © 2003-2009 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |